Beneficiaries of negotiated reimbursement drugs
Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines.
Unit million Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Beneficiaries of negotiated reimbursement drugs
China, as of 31 Oct 2024
Every record
All records
2 records · 1 region · 2018–2024
| Period | Value | Source | Type |
|---|---|---|---|
| China 2 records | |||
| as of 31 Oct 2024 | 830 million | NHSA · 28 Nov 2024 | actual |
| as of 31 Oct 2024 | 830 million | State Council · 31 Oct 2024 | actual |
Primary documents
Sources
2 documents. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 | NHSA | 28 Nov 2024 | 1 |
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 | State Council | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Beneficiaries of negotiated reimbursement drugs. Retrieved from https://statorigin.org/indicators/beneficiaries-of-negotiated-reimbursement-drugs